First Impressions on Healthscope (HSO) Interim Results

Bell Potter


Healthscopes divisional EBITDA in hospitals went up 10.4% to $327.6m, EBITDA margin was also up 80bp to 17.7%. International Pathology was up 13.7% to $60m and EBITDA margin up 120bp to 24.7%. Medical Centres up 0.3% to $15m and EBITDA margin up 10bp to 24.7%. Discontinued Australian Pathology business' operating EBITDA was down 33% to $7.5m and EBITDA margin down 110bp to 2.7% . Healthscopes outlook: “FY15 has been a successful year for Healthscope and our revenue strategies, combined with our cost strategies around labour and procurement, will continue to deliver further improvements in FY16. During the second half of FY16 we will also commission some large capital projects (Gold Coast, Knox, National Capital) which will lay the foundation for accelerated growth in FY17 and beyond.” Read our full summary here: (VIEW LINK)

1 stock mentioned

Bell Potter Securities is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to a diversified client base that includes individuals, institutions and corporations.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.